

State of Oklahoma SoonerCare Retevmo™ (Selpercatinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy Billing (NDC:) Start Date (or d	ate of next dose):
Dose:	Regimen:	
	Billing Provider Informa	tion
Pharmacy NPI:	Pharmacy Name	:
Pharmacy Phone:	Pharmacy Fax:	
	Prescriber Informatio	n
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
B. Is tumor RET-rearra C. Will selpercatinib be Thyroid Cancer A. Is diagnosis advance Yes No B. Will selpercatinib be C. Does member requiration Yes No D. Is diagnosis RET fustional in If yes, does merial in Is radioactive ion a. If appropriation If answer is none of the Additional Information:	nt, advanced or metastatic NSCLO ngement positive? Yes No used as a single-agent? Yes ed or metastatic medullary thyroid used as a single-agent? Yes re systemic therapy for <i>RET</i> -mutar sion-positive thyroid cancer? Yes_ mber require systemic therapy? Yes dine appropriate for this member? te, is member refractory to radioace above, please indicate diagnose	cancer or thyroid cancer? No nt medullary thyroid cancer? No es No Yes No ctive iodine? Yes No
For Continued Authorization: 1. Date of last dose: 2. Does member have any evid 3. Has the member experienced of yes, please specify adverse results.	ence of progressive disease while dadverse drug reactions related to eactions:	on selpercatinib? Yes No o selpercatinib therapy? Yes No
the best of my knowledge.		Date:nd all information is true and correct to necessary. Failure to complete this form in fullwill

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.